These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1024 related articles for article (PubMed ID: 31961766)

  • 1. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
    J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
    Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
    N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
    Makker V; Colombo N; Casado Herráez A; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay S; Ray-Coquard I; Shapira-Frommer R; Ushijima K; Sakata J; Yonemori K; Kim YM; Guerra EM; Sanli UA; McCormack MM; Smith AD; Keefe S; Bird S; Dutta L; Orlowski RJ; Lorusso D;
    N Engl J Med; 2022 Feb; 386(5):437-448. PubMed ID: 35045221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
    Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.
    Makker V; Taylor MH; Oaknin A; Casado Herraez A; Orlowski R; Dutta L; Ren M; Zale M; O'Malley DM
    Oncologist; 2021 Sep; 26(9):e1599-e1608. PubMed ID: 34190370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
    Makker V; Taylor MH; Aghajanian C; Oaknin A; Mier J; Cohn AL; Romeo M; Bratos R; Brose MS; DiSimone C; Messing M; Stepan DE; Dutcus CE; Wu J; Schmidt EV; Orlowski R; Sachdev P; Shumaker R; Casado Herraez A
    J Clin Oncol; 2020 Sep; 38(26):2981-2992. PubMed ID: 32167863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
    Rahma OE; Tyan K; Giobbie-Hurder A; Brohl AS; Bedard PL; Renouf DJ; Sharon E; Streicher H; Hathaway E; Cunningham R; Manos M; Severgnini M; Rodig S; Stephen Hodi F
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
    Mo DC; Luo PH; Huang SX; Wang HL; Huang JF
    Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).
    Molina AM; Hutson TE; Larkin J; Gold AM; Wood K; Carter D; Motzer R; Michaelson MD
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):181-9. PubMed ID: 24190702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
    Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM
    J Clin Oncol; 2020 Sep; 38(26):2960-2970. PubMed ID: 32716739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
    Atkins MB; Hodi FS; Thompson JA; McDermott DF; Hwu WJ; Lawrence DP; Dawson NA; Wong DJ; Bhatia S; James M; Jain L; Robey S; Shu X; Homet Moreno B; Perini RF; Choueiri TK; Ribas A
    Clin Cancer Res; 2018 Apr; 24(8):1805-1815. PubMed ID: 29358500
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
    Kawazoe A; Fukuoka S; Nakamura Y; Kuboki Y; Wakabayashi M; Nomura S; Mikamoto Y; Shima H; Fujishiro N; Higuchi T; Sato A; Kuwata T; Shitara K
    Lancet Oncol; 2020 Aug; 21(8):1057-1065. PubMed ID: 32589866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.
    Motzer RJ; Choueiri TK; Hutson T; Young Rha S; Puente J; Lalani AA; Winquist E; Eto M; Basappa NS; Tannir NM; Vaishampayan U; Bjarnason GA; Oudard S; Grünwald V; Burgents J; Xie R; McKenzie J; Powles T
    Eur Urol; 2024 Jul; 86(1):4-9. PubMed ID: 38582713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
    González-Martín A; Chung HC; Saada-Bouzid E; Yanez E; Senellart H; Cassier PA; Basu B; Corr BR; Girda E; Dutcus C; Okpara CE; Ghori R; Jin F; Groisberg R; Lwin Z
    Gynecol Oncol; 2024 Jul; 186():182-190. PubMed ID: 38718741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
    How JA; Patel S; Fellman B; Lu KH; Hwu P; Ramondetta LM; Westin SN; Fleming ND; Soliman PT; Jazaeri AA
    Gynecol Oncol; 2021 Jul; 162(1):24-31. PubMed ID: 33958211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
    Fishman MN; Srinivas S; Hauke RJ; Amato RJ; Esteves B; Cotreau MM; Strahs AL; Slichenmyer WJ; Bhargava P; Kabbinavar FF
    Eur J Cancer; 2013 Sep; 49(13):2841-50. PubMed ID: 23726267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
    Albiges L; Gurney H; Atduev V; Suarez C; Climent MA; Pook D; Tomczak P; Barthelemy P; Lee JL; Stus V; Ferguson T; Wiechno P; Gokmen E; Lacombe L; Gedye C; Perini RF; Sharma M; Peng X; Lee CH
    Lancet Oncol; 2023 Aug; 24(8):881-891. PubMed ID: 37451291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.